Literature DB >> 23033314

Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer.

Masaki Shiota1, Akira Yokomizo, Seiji Naito.   

Abstract

Oxidative stress caused by an increase in reactive oxygen species levels or a decrease in cellular antioxidant capacity can evoke the modulation of various cellular events including androgen receptor (AR) signaling via direct or indirect interactions. In this review, we summarize the mechanisms of AR activation by oxidative stress including: i) AR overexpression; ii) AR activation by AR co-regulators or intracellular signal transduction pathways; iii) generation of AR mutations or splice variants; and iv) de novo androgen synthesis. AR signaling augmented by oxidative stress appears to contribute to pro-survival and anti-apoptotic effects in prostate cancer cells in response to androgen deprivation therapy. In addition, AR signaling suppresses anti-survival and pro-apoptotic effects in prostate cancer cells in response to various cytotoxic and tumor-suppressive interventions including taxanes and radiation through the modulation of βIII-tubulin and ataxia telangiectasia-mutated kinase expression respectively. Taken together, AR signaling appears to render prostate cancer cells refractory to various therapeutic interventions including castration, taxanes, and radiation, indicating that AR signaling is a comprehensive resistant factor and crucial target for prostate cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23033314     DOI: 10.1530/ERC-12-0232

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  23 in total

1.  Efficacy of androgen deprivation therapy and the role of oxidative stress.

Authors:  D K Price
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

2.  Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress.

Authors:  Joo Hyoung Lee; Minsung Kang; Hong Wang; Gurudatta Naik; James A Mobley; Guru Sonpavde; W Timothy Garvey; Victor M Darley-Usmar; Selvarangan Ponnazhagan
Journal:  FASEB J       Date:  2017-01-09       Impact factor: 5.191

3.  Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.

Authors:  Masaki Shiota; Akira Yokomizo; Ario Takeuchi; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Seiji Naito
Journal:  Support Care Cancer       Date:  2014-07-05       Impact factor: 3.603

4.  Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells.

Authors:  Trinath P Das; Suman Suman; Chendil Damodaran
Journal:  Mol Carcinog       Date:  2013-03-08       Impact factor: 4.784

Review 5.  On the origins of the androgen receptor low molecular weight species.

Authors:  Maria Mudryj; Clifford G Tepper
Journal:  Horm Cancer       Date:  2013-07-17       Impact factor: 3.869

6.  USP2a alters chemotherapeutic response by modulating redox.

Authors:  B Benassi; M Marani; M Loda; G Blandino
Journal:  Cell Death Dis       Date:  2013-09-26       Impact factor: 8.469

7.  Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Authors:  Simone Mariani; Luana Lionetto; Michele Cavallari; Andrea Tubaro; Debora Rasio; Cosimo De Nunzio; Gena M Hong; Marina Borro; Maurizio Simmaco
Journal:  Int J Mol Sci       Date:  2014-01-21       Impact factor: 5.923

8.  An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer.

Authors:  Miho Ushijima; Masaki Shiota; Takashi Matsumoto; Eiji Kashiwagi; Junichi Inokuchi; Masatoshi Eto
Journal:  Cancer Sci       Date:  2022-04-01       Impact factor: 6.518

9.  Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.

Authors:  Shimpei Yamashita; Yasuo Kohjimoto; Takashi Iguchi; Hiroyuki Koike; Hiroki Kusumoto; Akinori Iba; Kazuro Kikkawa; Yoshiki Kodama; Nagahide Matsumura; Isao Hara
Journal:  BMC Urol       Date:  2016-03-22       Impact factor: 2.264

Review 10.  Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.

Authors:  Zhiqiang Qin; Xiao Li; Jianzhong Zhang; Jingyuan Tang; Peng Han; Zhen Xu; Yajie Yu; Chengdi Yang; Chengming Wang; Ting Xu; Zicheng Xu; Qing Zou
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.